Abstract
Peptide targeted 64Cu-labelled diagnostic agents for positron emission tomography are viable candidates for molecular imaging of cancer. In a clinical setting, optimal image quality relies on selective tumor uptake of the 64Culabelled radiotracer. The three components of the radiotracer construct – the chelate group, linker and targeting peptide – all influence the biodistribution of the 64Cu-labelled radiotracer in vivo. Low or moderate Cu complex stability in vivo results in transmetallation of 64Cu to endogenous proteins, giving rise to high background activity. The length and the nature of the linker group affect the affinity of the 64Cu-labelled radiotracer for the target receptor. Variations in the peptide sequence can impact on the metabolic stability and therefore the bioavailability and tumor retention of the 64Cu-labelled radiotracer in vivo. Lastly, the hydrophilicity of the construct can influence radiotracer metabolism and clearance pathways. Recent advances in the field of peptide targeted 64Cu-labelled radiopharmaceuticals involve GRPR-targeted and αvβ3 integrin receptor-targeted constructs. These constructs are based on the bombesin peptide sequence and the RGD recognition motif respectively. These examples are reviewed as case studies in the optimisation of 64Cu radiotracer design.
Keywords: Copper-64, radiopharmaceuticals, positron emission tomography, imaging, bombesin, gastrin-releasing peptide receptor, RGD, integrin receptor, Molecular imaging, PET technology, 64Cu2+ complex, somatostatin receptors, integrin v3, 64Cu-chelate complex
Current Topics in Medicinal Chemistry
Title: Peptide Targeted Copper-64 Radiopharmaceuticals
Volume: 11 Issue: 5
Author(s): Michelle T. Ma and Paul S. Donnelly
Affiliation:
Keywords: Copper-64, radiopharmaceuticals, positron emission tomography, imaging, bombesin, gastrin-releasing peptide receptor, RGD, integrin receptor, Molecular imaging, PET technology, 64Cu2+ complex, somatostatin receptors, integrin v3, 64Cu-chelate complex
Abstract: Peptide targeted 64Cu-labelled diagnostic agents for positron emission tomography are viable candidates for molecular imaging of cancer. In a clinical setting, optimal image quality relies on selective tumor uptake of the 64Culabelled radiotracer. The three components of the radiotracer construct – the chelate group, linker and targeting peptide – all influence the biodistribution of the 64Cu-labelled radiotracer in vivo. Low or moderate Cu complex stability in vivo results in transmetallation of 64Cu to endogenous proteins, giving rise to high background activity. The length and the nature of the linker group affect the affinity of the 64Cu-labelled radiotracer for the target receptor. Variations in the peptide sequence can impact on the metabolic stability and therefore the bioavailability and tumor retention of the 64Cu-labelled radiotracer in vivo. Lastly, the hydrophilicity of the construct can influence radiotracer metabolism and clearance pathways. Recent advances in the field of peptide targeted 64Cu-labelled radiopharmaceuticals involve GRPR-targeted and αvβ3 integrin receptor-targeted constructs. These constructs are based on the bombesin peptide sequence and the RGD recognition motif respectively. These examples are reviewed as case studies in the optimisation of 64Cu radiotracer design.
Export Options
About this article
Cite this article as:
T. Ma Michelle and S. Donnelly Paul, Peptide Targeted Copper-64 Radiopharmaceuticals, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785172
DOI https://dx.doi.org/10.2174/156802611794785172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy
Current Pharmaceutical Biotechnology The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Accuracy of Magnetic Resonance Spectroscopy in Discrimination of Neoplastic and Non-Neoplastic Brain Lesions
Current Medical Imaging A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu- DOTA-Nimotuzumab
Current Radiopharmaceuticals Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Implication of Aberrant Glycosylation in Cancer and Use of Lectin for Cancer Biomarker Discovery
Protein & Peptide Letters Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update
Anti-Cancer Agents in Medicinal Chemistry Magnetic Nanoparticles for MRI of Brain Tumors
Current Pharmaceutical Biotechnology Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology